Evidence-based recommendations for cancer nausea and vomiting

Journal of Clinical Oncology

Volumn 26, Issue 23, 2008, Pages 3903-3910

  Naeim, Arash ^a   Dy, Sydney M ^a   Lorenz, Karl A ^a   Sanati, Homayoon ^a   Walling, Anne ^a   Asch, Steven M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CHLORPROMAZINE; CYCLIZINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DROPERIDOL; FENTANYL; GRANISETRON; HALOPERIDOL; METOCLOPRAMIDE; MORPHINE; OCTREOTIDE; ONDANSETRON; OPIATE; PALONOSETRON; PLACEBO; RAMOSETRON; SCOPOLAMINE; SEROTONIN 2 ANTAGONIST; TROPISETRON;

ACUPUNCTURE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INTESTINE SURGERY; NASOGASTRIC TUBE; NAUSEA; NEOPLASM; OUTPATIENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCREENING; SMALL INTESTINE OBSTRUCTION; STENT; STOMACH TUBE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; ELECTROACUPUNCTURE; EVIDENCE-BASED MEDICINE; HUMANS; INTESTINAL OBSTRUCTION; MORPHOLINES; NAUSEA; NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 51349126924     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.9533     Document Type: Review

References (54)

1. Morran C, Smith DC, Anderson DA, et al: Incidence of nausea and vomiting with cytotoxic chemotherapy: A prospective randomised trial of antiemetics. Br Med J 1:1323-1324, 1979
2. Morrow GR, Lindke J, Black PM: Predicting development of anticipatory nausea in cancer patients: Prospective examination of eight clinical characteristics. J Pain Symptom Manage 6:215-223, 1991
3. Wilcox PM, Fetting JH, Nettesheim KM, et al: Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 66:1601-1604, 1982
4. National Comprehensive Cancer Network: Antiemesis. http://www.nccn.org/ professionals/physician_gls/PDF/antiemesis.pdf
5. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving highdose cisplatin - The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119, 2003
6. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098, 2003
7. Vainio A, Auvinen A: Prevalence of symptoms among patients with advanced cancer: An international collaborative study - Symptom Prevalence Group. J Pain Symptom Manage 12:3-10, 1996
8. Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947, 2006
9. Roila F, Hesketh PJ, Herrstedt J: Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28, 2006
10. Teunissen SC, Wesker W, Kruitwagen C, et al: Symptom prevalence in patients with incurable cancer: A systematic review. J Pain Symptom Manage 34:94-104, 2007
11. National Comprehensive Cancer Network: Palliative care. http://www.nccn.org/professionals/physician_gls/PDF/palliative.pdf
12. Hesketh PJ, Kris MG, Grunberg SM, et al: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109, 1997
13. Gralla RJ, Osoba D, Kris MG, et al: Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines - American Society of Clinical Oncology. J Clin Oncol 17:2971-2994, 1999
14. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC): Prevention of chemotherapy- and radiotherapy-induced emesis: Results of Perugia Consensus Conference. Ann Oncol 9:811-819, 1998
15. Navari RM, Reinhardt RR, Gralla RJ, et al: Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist: L-754,030 Antiemetic Trials Group. N Engl J Med 340:190-195, 1999
16. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al: Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000-1006, 2006
17. Warr DG, Grunberg SM, Gralla RJ, et al: The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41:1278-1285, 2005
18. de Wit R, Herrstedt J, Rapoport B, et al: The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: A combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 40:403-410, 2004
19. Hesketh PJ, Grunberg SM, Herrstedt J, et al: Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: Effect of gender on treatment response. Support Care Cancer 14:354-360, 2006
20. Herrstedt J, Muss HB, Warr DG, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548-1555, 2005
21. Cubeddu LX, Pendergrass K, Ryan T, et al: Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies: Ondansetron Study Group. Am J Clin Oncol 17:137-146, 1994
22. Jantunen IT, Kataja VV, Muhonen TT, et al: An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 33:66-74, 1997
23. The Italian Group for Antiemetic Research: Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-1559, 2000
24. Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005
25. Warr D, Wilan A, Venner P, et al: A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis: An NCI Canada Clinical Trials Group phase III trial. Eur J Cancer 29A:33-36, 1992
26. Cheirsilpa A, Sinthusake T, Songsakkaesorn A, et al: Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin-based chemotherapy: A randomized controlled trial. Jpn J Clin Oncol 35:695-699, 2005
27. del Giglio A, Soares HP, Caparroz C, et al: Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: Results of a meta-analysis of randomized controlled trials. Cancer 89:2301-2308, 2000
28. Jordan K, Hinke A, Grothey A, et al: Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: A pooled analysis. Support Care Cancer 13:26-31, 2005
29. Koo WH, Ang PT: Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7:71-74, 1996
30. Systemic Treatment Disease Site Group: Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Practice guideline No. 12-3. Toronto, Ontario, Canada, Cancer Care Ontario, 2003
31. Geling O, EichlerHG:Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289-1294, 2005
32. Lindley C, Goodin S, McCune J, et al: Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: Comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol 28:270-276, 2005
33. Cancer Care Ontario: The role of neurokinin-1 receptor antagonists in the prevention of emesis due to high-dose cisplatin. http://www.cancercare.on.ca/ pdf/pebc12-4f.pdf
34. Ioannidis JP, Hesketh PJ, Lau J: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol 18:3409-3422, 2000
35. Ezzo JM, Richardson MA, Vickers A, et al: Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2:CD002285, 2006
36. Ezzo J, Vickers A, Richardson MA, et al: Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 23:7188-7198, 2005
37. Ezzo J, Streitberger K, Schneider A: Cochrane systematic reviews examine P6 acupuncture-point stimulation for nausea and vomiting. J Altern Complement Med 12:489-495, 2006
38. Shen J, Wenger N, Glaspy J, et al: Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA 284:2755-2761, 2000
39. Glare P, Pereira G, Kristjanson LJ, et al: Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer 12:432-440, 2004
40. Critchley P, Plach N, Grantham M, et al: Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: A systematic review. J Pain Symptom Manage 22:631-634, 2001
41. Bruera E, Moyano JR, Sala R, et al: Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: A randomized controlled trial. J Pain Symptom Manage 28:381-388, 2004
42. McNicol E, Horowicz-Mehler N, Fisk RA, et al: Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain 4:231-256, 2003
43. Ripamonti C, Mercadante S, Groff L, et al: Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomized trial. J Pain Symptom Manage 19:23-34, 2000
44. Tilney HS, Lovegrove RE, Purkayastha S, et al: Comparison of colonic stenting and open surgery for malignant large bowel obstruction. Surg Endosc 21:225-233, 2007
45. Dormann A, Meisner S, Verin N, et al: Self-expanding metal stents for gastroduodenal malignancies: Systematic review of their clinical effectiveness. Endoscopy 36:543-550, 2004
46. Feuer DJ, Broadley KE, Shepherd JH, et al: Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer: The Systematic Review Steering Committee. Gynecol Oncol 75:313-322, 1999
47. Cannizzaro R, Bortoluzzi F, Valentini M, et al: Percutaneous endoscopic gastronomy as a decompressive technique in bowel obstruction due to a abdominal carcinomatosis. Endoscopy 27:317-320, 1995
48. Campagnutta E, Cannizzaro R, Gallo A, et al: Palliative treatment of upper intestinal obstruction by gynecological malignancy: The usefulness of percutaneous endoscopic gastrostomy. Gynecol Oncol 62:103-105, 1996
49. Cancer Care Ontario: The role of octreotide in the management of patients with cancer. http://www.cancercare.on.ca/pdf/pebc12-7f.pdf
50. Mystakidou K, Tsilika E, Kalaidopoulou O, et al: Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: A randomized, double- blind, controlled clinical trial. Anticancer Res 22:1187-1192, 2002
51. Mercadante S, Ripamonti C, Casuccio A, et al: Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 8:188-191, 2000
52. Feuer DJ, Broadley KE: Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2:CD001219, 2000
53. Laval G, Girardier J, Lassauniere JM, et al: The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: Do they remove the obstruction? Palliat Med 14:3-10, 2000
54. Hardy J, Ling J, Mansi J, et al: Pitfalls in placebo-controlled trials in palliative care: Dexamethasone for the palliation of malignant bowel obstruction. Palliat Med 12:437-442, 1998